Last reviewed · How we verify
XL888
At a glance
| Generic name | XL888 |
|---|---|
| Also known as | molecule inhibitor, Hsp90 inhibitor, EXEL-4888, EXEL-04354888, Heat Shock Protein 90 Inhibitor XL888 |
| Sponsor | Exelixis |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (PHASE1)
- Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer (PHASE1)
- Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (PHASE1)
- Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XL888 CI brief — competitive landscape report
- XL888 updates RSS · CI watch RSS
- Exelixis portfolio CI